Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 1—January 2014
Dispatch

Detection of Infectivity in Blood of Persons with Variant and Sporadic Creutzfeldt-Jakob Disease

Jean Yves Douet, Saima Zafar, Armand Perret-Liaudet, Caroline Lacroux, Séverine Lugan, Naima Aron, Herve Cassard, Claudia Ponto, Fabien Corbière, Juan Maria Torres, Inga Zerr, and Olivier AndreolettiComments to Author 
Author affiliations: Institut National de la Recherche Agronomique/Ecole Nationale Vétérinaire, Toulouse, France (J.Y. Douet, C. Lacroux, S. Lugan, N. Aron, H. Cassard, F. Corbière, O. Andréoletti); National Reference Center for Transmissible Spongiform Encephalopathy, Georg August University, Göttingen, Germany (S. Zafar, C. Ponto, I. Zerr); Hospices Civils de Lyon, France (A. Perret-Liaudet); BioRan, Bron, France (A. Perret-Liaudet); Centro de Investigación en Sanidad Animal, Madrid, Spain (J.M. Torres)

Main Article

Table 2

Intracerebral inoculation of blood components collected from 1 vCJD and 4 sCJD cases (MM1) in transgenic mice expressing the bovine or human prion protein gene*†

Mouse model Donor Specimen Inoculated
mice Positive
mice Incubation period, d ID/mL (95%CI)‡
tgBov vCJD Leukocyte 24 3 476, 567, 576 2.23 (0–4.87)
Plasma 24 1 453 2.12 (0–6.52)
Erythrocyte 24 1 433 2.12 (0–6.52)
tgHu sCJD case 1 Plasma 14§ 1 338 3.70 (0–11.65)
Brain 6 6 216 ± 2 NA
sCJD case 2 Plasma 24 0 >700 0 (0- 6.24)
brain 6 6 217 ± 5 NA
sCJD case 3 Plasma 24 1 233 2.12 (0–6.52)
Brain 6 6 205 ± 5 NA
sCJD case 4 Plasma 24 0 >700 0 (0–6.24)
Brain 6 6 207 ± 3 NA
tgHu Control human Plasma 12 0 >650 NA
tgBov Control human Plasma 12 0 >650 NA
tgHu Control human PBS 12 0 >700 NA
tgBov Control human PBS 12 0 >700 NA
tgHu Control human Brain 24 0 >700 NA
tgBov Control human Brain 24 0 >700 NA
tgHu Control human None 24 0 >750 NA
tgBov Control human None 24 0 >750 NA

*vCJD, variant Creutzfeld-Jakob disease; sCJD, sporadic Creutzfeld-Jakob disease; dpi, days postinfection; ID, infectious dose; tgBov, bovine prion protein; tgHu, human prion protein;; PBS, phosphate-buffered saline.
†The leukocyte(s) from a single vCJD case corresponding to a starting volume of 3 mL of blood were suspended in 1 mL of 5% glucose solution. The leukocyte suspension and the crude erythrocytes were homogenized by using a high speed cell disrupter. The leukocyte and erythrocyte homogenates (vCJD case) and crude plasma (vCJD and sCJD cases) were intracerebrally injected into mice (20 µL per mouse). For the 4 sCJD MM1 cases, brain homogenate (10%, temporal cortex) were also inoculated in tgHu. Mice were euthanized when they showed clinical signs of infection or after 650 or 750 dpi. Mice were considered infected when abnormal protease-resistant prion protein; deposition was detected in brain tissue by using Western blot analysis with Sha31 monoclonal antibody: epitope amino acids 145–152 (YEDRYYRE) of the sheep PrP sequence. For samples showing 100% attack rate, incubation periods are reported as mean (± SD). For other samples, individual incubation period of CJD-positive mice are presented; their infectious titers were estimated by using limiting dilution titration method (application of Poisson model) described by Brown et al (13).
‡Leukocyte titer is expressed as ID/mL of the starting whole blood. Plasma and erythrocyte titers are expressed as ID/mL of inoculum.
§24 mice were inoculated; 10 died because of the acute toxicity of the sample.

Main Article

References
  1. Parchi  P, Castellani  R, Capellari  S, Ghetti  B, Young  K, Chen  SG, Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996;39:76778. DOIPubMed
  2. Brown  P, Brandel  JP, Sato  T, Nakamura  Y, MacKenzie  J, Will  RG, Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis. 2012;18:9017. DOIPubMed
  3. Brown  P, Cervenakova  L, Diringer  H. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J Lab Clin Med. 2001;137:513. DOIPubMed
  4. Brown  P, Gibbs  CJ Jr, Rodgers-Johnson  P, Asher  DM, Sulima  MP, Bacote  A, Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol. 1994;35:51329 . DOIPubMed
  5. Bruce  ME, Will  RG, Ironside  JW, McConnell  I, Drummond  D, Suttie  A, Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature. 1997;389:498501. DOIPubMed
  6. Peden  AH, Head  MW, Ritchie  DL, Bell  JE, Ironside  JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:5279. DOIPubMed
  7. Peden  A, McCardle  L, Head  MW, Love  S, Ward  HJ, Cousens  SN, Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia. 2010;16:296304. DOIPubMed
  8. Bruce  ME, McConnell  I, Will  RG, Ironside  JW. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet. 2001;358:2089. DOIPubMed
  9. Andréoletti  O, Litaise  C, Simmons  H, Corbiere  F, Lugan  S, Costes  P, Highly efficient prion transmission by blood transfusion. PLoS Pathog. 2012;8:e1002782. DOIPubMed
  10. Béringue  V, Vilotte  JL, Laude  H. Prion agent diversity and species barrier. Vet Res. 2008;39:47. DOIPubMed
  11. Castilla  J, Gutiérrez Adán  A, Brun  A, Pintado  B, Ramirez  MA, Parra  B, Early detection of PrPres in BSE-infected bovine PrP transgenic mice. Arch Virol. 2003;148:67791. DOIPubMed
  12. Padilla  D, Beringue  V, Espinosa  JC, Andreoletti  O, Jaumain  E, Reine  F, Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. PLoS Pathog. 2011;7:e1001319. DOIPubMed
  13. Markus  RA, Frank  J, Groshen  S, Azen  SP. An alternative approach to the optimal design of an LD50 bioassay. Stat Med. 1995;14:84152 . DOIPubMed
  14. Brown  P, Cervenakova  L, McShane  LM, Barber  P, Rubenstein  R, Drohan  WN. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion. 1999;39:116978. DOIPubMed

Main Article

Page created: January 03, 2014
Page updated: January 03, 2014
Page reviewed: January 03, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external